Accessibility Menu
Mainz Biomed logo

Mainz Biomed(NASDAQ) QUCY

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 YearN/A
1 Year-46%
1 Month-33%
N/A
Mainz Biomed last closing stock price
MetricPriceDate
Last closeUSD 1.102026-07-27
Mainz Biomed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.17%USD 1.162026-07-20
1 month-32.52%USD 1.632026-06-26
3 month+119.21%USD 0.502026-04-28
Year to date-1.79%USD 1.122025-12-31
1 year-46.08%USD 2.042025-07-25
3 year-99.35%USD 168.802023-07-28
Since inception-99.73%USD 399.602021-11-05

Mainz Biomed Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$2.49

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

N/A

QUCY News

DNA test, scientist

Why Mainz Biomed Stock Is Crashing Today

Keith SpeightsJan 26, 2022

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Mainz Biomed

Mainz Biomed B.V. is a German company focused on molecular genetics for cancer diagnostics. The firm develops in-vitro diagnostic tools and assays, primarily for clinical applications in human genetics, with a commitment to improving patient outcomes.

Products and Services
  • ColoAlert: A screening test for colorectal cancer detection
  • PancAlert: A product candidate for pancreatic cancer screening
  • GenoStrip: A solution for identifying pathogens in various environments
Growth Outlook
  • Expansion into new markets is anticipated with innovative diagnostic solutions
  • Increased demand for cancer screening tools is projected globally
  • Strategic partnerships may enhance product development and market reach
Financial Highlights
  • Recent quarterly revenue of 250,363 reflects ongoing development efforts
  • Trailing twelve months (TTM) revenue of 1,186,000 indicates growth potential
  • Cash and cash equivalents stood at 889,091, supporting operational needs
Mainz Biomed B.V. operates in the medical diagnostics and research sector, with a focus on innovative solutions for cancer detection. The company's flagship product, ColoAlert, is designed to enhance early detection of colorectal cancer, while PancAlert aims to address pancreatic cancer screening needs. GenoStrip further diversifies the product line by providing molecular genetic solutions for pathogen identification. The growth outlook for Mainz Biomed is promising, driven by an increasing global demand for effective cancer screening tools. The company is well-positioned to expand into new markets, leveraging its innovative diagnostic solutions. Strategic partnerships may also play a crucial role in enhancing product development and market penetration. Financially, Mainz Biomed has shown resilience, with a recent quarterly revenue of 250,363, reflecting ongoing efforts in product development. The trailing twelve months (TTM) revenue of 1,186,000 suggests a potential for growth as the company continues to innovate and expand its offerings. With cash and cash equivalents at 889,091, Mainz Biomed is equipped to support its operational needs and pursue future growth opportunities.
AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

13

CEO

Guido Baechler

Website

mainzbiomed.com

Headquarters

Mainz, 55129, DE

QUCY Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-2723.55%

Net Income Margin

-2937.85%

Return on Equity

-325.93%

Return on Capital

-403.51%

Return on Assets

-109.14%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$286.72K

Operating Income

-$7.81M

EBITDA

-$7.47M

Operating Cash Flow

-$5.28M

Capital Expenditure

-$250.56K

Free Cash Flow

-$5.53M

Cash & ST Invst.

$4.45M

Total Debt

$126.79K

Mainz Biomed Performance Analysis

Mainz Biomed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 529,877-8.2%
20232023-12-31USD 895,47969.0%
20242024-12-31USD 893,991-0.2%
20252025-12-31USD 537,080-39.9%
Mainz Biomed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Mainz Biomed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -74.5515.0%
20232023-12-31USD -64.76-13.1%
20242024-12-31USD -21.91-66.2%
20252025-12-31USD -2.70-87.7%
Mainz Biomed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

13

N/A

Net Income

-$5.08M

N/A

EBITDA

-$2.41M

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.45M

+355.1%

Total Debt

$126.79K

-98.5%

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

-100.0%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$126.79K

-98.0%

Return on Assets

-1.09%

N/A

Return on Invested Capital

-1.70%

N/A

Free Cash Flow

-$2.71M

N/A

Operating Cash Flow

-$2.71M

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,396.49-0.00%
^DJIDJI
$52,083.00+0.00%
^IXICNASDAQ
$24,847.16-0.01%
BTCBitcoin
$64,796.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
NOKNokia
$9.28+0.02%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About QUCY

What is the current price of Mainz Biomed?

Mainz Biomed is trading at N/A per share.

What is the 52-week range for Mainz Biomed?

Over the past 52 weeks, Mainz Biomed has traded between N/A and N/A.

How much debt does Mainz Biomed have?

As of the most recent reporting period, Mainz Biomed reported total debt of $126.79K.

How much cash does Mainz Biomed have on hand?

Mainz Biomed reported $4.45M in cash and cash equivalents in its most recent financial results.

What is Mainz Biomed’s dividend yield?

Mainz Biomed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services